Journal DOI 10.68956/dyh5-kwte

Creative Commons source reading · Alzheimer’s disease and related dementias

Mitochondria dysfunction in the pathogenesis of Alzheimer's disease: recent advances.

Wenzhang Wang; Fanpeng Zhao; Xiaopin Ma; George Perry; Xiongwei Zhu

Originally published in Molecular neurodegeneration · 2020-05-29

From the article

Selected source text. JournalOS removes markup and shortens excerpts where indicated. The full article provides the complete context.

Abstract

Alzheimer's disease (AD) is one of the most prevalent neurodegenerative diseases, characterized by impaired cognitive function due to progressive loss of neurons in the brain. Under the microscope, neuronal accumulation of abnormal tau proteins and amyloid plaques are two pathological hallmarks in affected brain regions. Although the detailed mechanism of the pathogenesis of AD is still elusive, a large body of evidence suggests that damaged mitochondria likely play fundamental roles in the pathogenesis of AD. It is believed that a healthy pool of mitochondria not only supports neuronal activity by providing enough energy supply and other related mitochondrial functions to neurons, but also guards neurons by minimizing mitochondrial related oxidative damage. In this regard, exploration of the multitude of mitochondrial mechanisms altered in the pathogenesis of AD constitutes novel promising therapeutic targets for the disease.

Conclusion

Mitochondrial dysfunction plays a critical role in AD either as a primary or secondary event, which could represent promising therapeutic targets (Fig. 1). One therapeutic strategy targeting mitochondria directly focuses on modulating mitochondrial activities such as bioenergetics. For example, oxaloacetate (OAA), a Krebs cycle and gluconeogenesis intermediate that enhanced bioenergetic fluxes and upregulated some brain bioenergetic infrastructure-related parameters, is in phase I clinical trial [254].

Editorial reading guide

  • Was the evidence cross-sectional, longitudinal or experimental?
  • How did the authors account for age, disease stage and differences among participants?